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HLA-B*81:01 and HLA-B*39:10 alleles have been associated with viremic control in HIV-1 subtype C infection. Both alleles re-
strict the TL9 epitope in p24 Gag, and cytotoxic-T-lymphocyte (CTL)-mediated escape mutations in this epitope have been asso-
ciated with an in vitro fitness cost to the virus. We investigated the timing and impact of mutations in the TL9 epitope on disease
progression in five B*81:01- and two B*39:10-positive subtype C-infected individuals. Whereas both B*39:10 participants sam-
pled at 2 months postinfection had viruses with mutations in the TL9 epitope, in three of the five (3/5) B*81:01 participants, TL9
escape mutations were only detected 10 months after infection, taking an additional 10 to 15 months to reach fixation. In the two
remaining B*81:01 individuals, one carried a TL9 escape variant at 2 weeks postinfection, whereas no escape mutations were de-
tected in the virus from the other participant for up to 33 months postinfection, despite CTL targeting of the epitope. In all par-
ticipants, escape mutations in TL9 were linked to coevolving residues in the region of Gag known to be associated with host tro-
pism. Late escape in TL9, together with coevolution of putative compensatory mutations, coincided with a spontaneous increase
in viral loads in two individuals who were otherwise controlling the infection. These results provide in vivo evidence of the detri-
mental impact of B*81:01-mediated viral evolution, in a single Gag p24 epitope, on the control of viremia.
Human leukocyte antigen (HLA) class 1 is the strongest predic-tor of HIV-1 disease progression (15, 44). Furthermore, cy-
totoxic-T-lymphocyte (CTL) responses have been associated with
control of viremia, in both acute and chronic HIV-1 infections (3,
21, 23, 26, 31, 32). However, individuals carrying beneficial HLAs
do not always have delayed disease progression (13). Understand-
ing the relationship between the virus and the host, and how HLA
differentially influences disease progression, remains a central
question in HIV research and optimal vaccine immunogen design
(40).
CTL responses targeting p24 Gag have been associated with
long-term control of HIV-1 replication (1, 2, 19, 21, 31). Indeed,
HLA alleles associated with control of viremia preferentially pres-
ent p24 Gag epitopes and in acute infection (2, 55). An analysis of
HLA-B*57/58:01 individuals from the same cohort as character-
ized for the present study found that individuals who targeted the
TW10 epitope had better virological control, which was not lost
following immune escape (7). Aside from HLA-B*57/58:01, there
is limited information on the impact of CTL immune escape in
individuals controlling infection in African cohorts, which may
differ from Caucasian cohorts due to differences in HLA allelic
frequency. HLA B7 supertype is very common in Black Africans
compared to Caucasians (20, 22). The HLA-B7 supertype includes
HLA-B*07:02, HLA-B*39:10, HLA-B*42:01, HLA-B*42:02, and
HLA-B*81:01 (34) and, within this supertype, only HLA-B*81:01
and HLA-B*39:10 alleles are consistently associated with the con-
trol of HIV-1 in subtype C chronic infection (34). The TL9 epitope
in p24 (Gag residues 180 to 188) is immunodominant, and al-
though all individuals positive for B7 alleles can restrict this
epitope, the magnitude of TL9-specific responses and the fre-
quency of the corresponding polymorphisms in this epitope are
higher in HLA-B*81:01- and HLA-B*39:10-positive individuals
compared to HLA-B*42:01-positive individuals. This difference
in recognition and selective pressure could be due to minor vari-
ations in these HLAs (18) or differences in HLA specificity (34),
which may contribute to their differential role in influencing dis-
ease progression.
Mutations in residues E177, Q182, and T186, located in or
proximal to the TL9 epitope, have been associated with immune
escape in the B*81:01-, B*42:01-, and B*39:10-positive individuals
(34). In vitro studies have shown that the E177D/A and T186S
mutations incur a fitness cost to the virus (47, 54, 56), whereas the
Q182S mutation reverts after transmission to HLA-mismatched
individuals, suggesting that it is not beneficial to the virus (39). We
provide here a detailed analysis of individuals with alleles belong-
ing to the HLA-B7 supertype recruited during acute/early infec-
tion and monitored for 3 years. We report on the timing and
frequency of escape in the TL9 epitope and elucidate the impact of
escape on disease progression in HLA-B*81:01- and HLA-B*39:
10-positive HIV-1 subtype C-infected participants.
MATERIALS AND METHODS
Study subjects. The CAPRISA 002 Acute Infection Cohort enrolled sub-
jects within 3 months of infection and monitored them until the initiation
of antiretroviral therapy according to South African National Guidelines
(defined at that time as CD4  200 cells/l or AIDS defining illness)
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(53). Women were enrolled from both the HIV-negative cohort and other
seroincidence cohorts in Durban, South Africa. HIV-1 infection was iden-
tified using rapid antibodies assay and PCR and was confirmed using an
enzyme immunoassay test as previously described (53). CD4 T cells
counts were assessed using a FACSCalibur flow cytometer, while viral
loads were measured using a Cobas Amplicor HIV-1 monitor test (v1.5;
Roche Diagnostics, Branchburg, NJ). Samples were collected at enroll-
ment, weekly for 3 weeks, fortnightly until 3 months, monthly until a year,
and quarterly thereafter. Written informed consent was obtained from all
participants. This study received ethical approval from the University of
KwaZulu-Natal, the University of Witwatersrand, and the University of
Cape Town.
HIV-1 plasma RNA isolation and sequencing. RNA was isolated
from plasma samples using either a Magna-Pure compact nucleic extrac-
tor (Roche) or manually using a QIAamp viral RNA extraction minikit
(Qiagen) for samples with plasma viral loads of 2,000 copies per ml. A
SuperScript III reverse transcription kit (Invitrogen) and two gene-spe-
cific primers—Gag D reverse (=5-AAT TCC TCC TAT CAT TTT TGG-3=;
HXB positions 2382 to 2402) and Nef OR (=5-AGG CAA GCT TTA TTG
AGG-3=; HXB positions 9608 to 9625) for gag and nef, respectively—were
used to transcribe cDNA from RNA. First- and second-round PCR and
sequencing primers for Gag were as previously described by Chopera et al.
(7). Using only the Gag B forward and Gag B reverse primers, only p24 gag
sequences were generated. Sequences were assembled using Chromaspro
(Technelysium, Pty., Ltd.) and aligned using the CLUSTAL W in Bioedit
(default settings) (52).
IFN- ELISpot assay. HIV-1-specific T-cell responses across the en-
tire HIV-1 clade C proteome were quantified by interferon gamma
(IFN-) enzyme-linked immunospot (ELISpot) assay using freshly iso-
lated and prepared peripheral blood mononuclear cells as previously de-
scribed (38). TL9 responses that were detected at the single-peptide level
within peptide pools were confirmed in a second ELISpot assay and mon-
itored longitudinally for these participants as previously described (27).
Responses were considered positive if there were 100 spot-forming
units (SFU)/106 cells (after subtraction of the background).
HLA typing. HLA class I genotyping was performed as previously
described (8). Exons 2, 3, and 4 were sequenced using Atria Allele
SEQR kits (Abbott Diagnostics) and Assign SBT 3.5 software (Conexio
Genomics).
Statistical analyses. Statistical analysis and graphical presentations
were implemented in Prism 5.0 (GraphPad Software, Inc.). To control for
fluctuations in viral loads and CD4 counts, the 12- and 36-month set
points of these parameters were calculated by taking the median of mea-
surements at three time points closest to 12 and 36 months, respectively.
To identify networks of interacting sites in the alignment, approaches
coupling phylogenetic and Bayesian network models in Spidermonkey
(45) were used (www.datamonkey.org). Repeated inferences with ances-
tral states sampled from the posterior distribution were used to evaluate
robustness (11) in identifying networks of interacting sites in an align-
ment using Bayesian network techniques, which assumes that coevolving
sites will tend to acquire mutations along the same set of branches (45).
Statistical analysis of significance was based on Mann-Whitney two-tailed
t test.
Nucleotide sequence accession numbers. Sequences for the present
study were submitted to GenBank under accession numbers JX434413 to
JX34485 and JX434486 to JX434595.
RESULTS
Of the 62 women recruited into the CAPRISA 002 acute infection
study, five were HLA-B*81:01 positive and two were B*39:10 pos-
itive (Table 1). Women were recruited at a median time point of 6
weeks postinfection (interquartile range [IQR]  4 to 8 weeks).
To evaluate gag evolution and the timing of escape in the B*81:01-
and B*39:10-restricted TL9 epitope, sequencing was performed
on samples collected at the earliest time point and every 3
months postinfection until 3 years or initiation of antiretrovi-
ral (ARV) therapy according to national guidelines (CD4 T-
cell counts  200 cells/l or AIDS-defining illness). Samples
from additional time points were sequenced to further refine
the timing of escape.
Influence of HLA-B*81:01 and HLA-B*39:10 on early and
chronic disease progression. To understand disease progression
in HLA-B*81:01/B*39:10-positive participants, we analyzed the
trajectory of viral loads and CD4 T-cell counts over a 4-year
postinfection period (Fig. 1).
Of the two B*39:10-positive participants, one was a progres-
sor (CAP289) and the other (CAP278) a controller. The
B*39:10 progressor maintained high viral loads from the first
year of infection (500,000 copies/ml), with lower median
CD4 T cells compared to the rest of the cohort. The B*39:10
controller maintained viral loads below 2,000 copies/ml and
had high CD4 T cells (600 cells/l) after 4 years of infection.
Of the five B*81:01-positive participants, one controlled her
viral load after 18 months of infection (CAP262); two partici-
pants who initially controlled viral replication below 2,000
copies/ml for the first 18 to 24 months of infection had viral
loads that increased by 1 log over a 6-month period and there-
after (CAP222 and CAP277). By 4 years postinfection, these
individuals had lower CD4 T-cell counts compared to individ-
uals with nonprotective alleles (i.e., B*81:01/57/58:01/39:10-
negative participants). Of the two remaining B*81:01 individ-
uals, CAP129 had a relatively high viral load, though with
increase in CD4 T-cell counts between years 3 and 4 postin-
fection, and CAP225 had typical viral loads which declined
between years 3 and 4 postinfection with a concomitant in-
crease in CD4 T-cell count.
We then investigated the influence of HLA-B*81:01 and HLA-
B*39:10 on viral load set point and CD4 T-cell counts at 1 and 3
years postinfection. B*57/58:01 participants were analyzed sepa-
rately since these “protective” alleles are often associated with bet-
ter control of HIV-1 replication (41, 42). Although the median
viral load at set point (1 year postinfection) was lower in B*81:01-
positive participants compared to those with nonprotective alleles
(i.e., B*81:01/57/58:01/39:10-negative participants), this was
not significant (P  0.2) (Fig. 2A; median, 3.57 log10 copies/ml
[IQR  2.7 to 4.6] versus 4.46 log10 copies/ml [IQR  3.49 to
4.8]). There were, however, significantly higher CD4 T-cell
counts for the B*81:01-positive participants compared to individ-
uals with nonprotective alleles at 1 year postinfection (P  0.049)
TABLE 1 HLA type 1for the five B*81:01- and two B*39:10-positive





CAP0129 26:01, 80:01 18:01, 81:01 02:02, 04:01
CAP0222 30:01, 33:03 53:01, 81:01 04:01, 04:01
CAP0225 01:01, 30:01 42:02, 81:01 17:01, 18:01
CAP0262 01:01, 66:02 42:01, 81:01 17:01, 18:01
CAP0277 30:09, 43:01 58:02, 81:01 04:01, 04:01
CAP0278 30:01, 43:01 39:10, 42:02 12:03, 17:01
CAP0289 30:02, 68:01 39:10, 58:02 06:02, 12:03
a PID, participant identification number.
Ntale et al.
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(Fig. 2B; median, 597 cells/l [IQR  467 to 644] versus 369
cells/l [IQR  305 to 525]). To determine whether these HLA
alleles affected disease progression in chronic infection, we ana-
lyzed both viral loads and CD4 T-cell counts at 3 years post-
infection. By 3 years postinfection, 12 participants had initiated
ARV therapy and, in order to not bias the analysis toward the
controllers, we used the last available viral load and CD4 count
data for these subjects prior to their commencing ARV therapy.
We found no significant differences in either viral load or CD4
T-cell counts at 3 years postinfection (Fig. 2) or 4 years (data not
shown) in B*81:01-positive participants compared to those with
nonprotective alleles, suggesting that this potential benefit de-
tected at 12 months was not sustained in chronic infection.
We further investigated whether B*81:01-positive participants
controlled infection better than B*57/58:01-positive participants.
Although at 1 year, the CD4 T-cell counts tended to be higher
and viral loads lower in B*81:01-positive participants compared
to B*57/58:01-positive participants, this difference was not signif-
icant, and this trend was not sustained at 3 years (Fig. 2C and D).
Of the two B*39:10-positive participants, one was a controller,
whereas the other was a typical disease progressor (Fig. 1). The
controller had a viral load at 1 year of 2.95 log10 copies/ml com-
FIG 1 (A) Viral load and (B) CD4 T-cell count trajectories for the first 48 months of infection for five HLA-B*81:01-positive participants (CAP129, CAP222,
CAP225, CAP262 and CAP277; represented by squares) and two B*39:10-positive participants (CAP278 and CAP289; represented by triangles). CAP289 had not
reached 48 months postinfection by the time of this study. The trajectory of median viral loads and median CD4 T-cell counts for all other CAPRISA
participants (OTHERS), excluding B*39:10/81:01 and B*57/58:01, are shown as dotted red lines. The broken black line represents the viral load level of 2,000
copies/ml, defining controllers. Viral loads and CD4 T-cell counts were smoothed at each time point (medians of measurements taken at three time points
closest to intervals 3, 6, 9, 12, 15, etc., up to 48 months postinfection).
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pared to 5.72 log10 copies/ml for the progressor, while their re-
spective CD4 T-cell counts were 568 and 410 cells/l (Fig. 2).
Linkage to HLA-Cw alleles did not impact disease progres-
sion. In subtype C infection, a good clinical outcome in individ-
uals positive for B*81:01 and B*39:10 alleles has been linked to an
additive impact of the Cw*04:01 and Cw*12:03 alleles, respec-
tively (33). Of the five B*81:01-positive participants, three partic-
ipants were positive for the Cw*04:01 allele, of which two were
controllers (CAP222 and CAP277) and the third was a typical
progressor (CAP129). However, of the two B*81:01-positive par-
ticipants who did not carry the Cw*04:01 allele, one was a typical
progressor (CAP225), while the other was a controller (CAP262).
Although both of the B*39:10-positive participants were also pos-
itive for the Cw*12:03 allele (Table 1), one was a progressor and
the other was a controller (Fig. 1). These results suggest that the
differential disease progression in B*81:01- or B*39:10-positive
participants was not simply due to the HLA-Cw allelic combina-
tions.
Kinetics of p24-Gag-TL9 escape in B*39:10- and B*81:01-
positive participants. Substitutions in positions E177, Q182, and
T186 Gag residues that are located within or proximal to the TL9
epitope (Gag180-188) result in the loss of immune recognition in
B*81:01/B*39:10-positive individuals, with the predominant
polymorphisms associated with HLA-mediated TL9 restriction in
vivo being E177D, Q182S, and T186S (16, 34, 39, 47).
In B*81:01-positive participants, mutations in TL9 generally
emerged later in infection (Table 2). The first mutation to emerge
was at position 182. In three participants who selected this muta-
tion postinfection, the Q182X (where X  S/T/A/H) was detected
between at 70 and 83 weeks postinfection in CAP222, at 50 and 61
weeks in CAP225, and at 48 and 50 weeks in CAP277. In two of the
three participants (CAP222 and CAP277), additional escape mu-
tations were detected within 6 to 12 months after the emergence of
the escape mutation at position 182 and reached fixation only 10
to 15 months later (Table 2). The T186S mutation emerged either
alone as in CAP277 or concurrently with E177D, as in CAP222.
In the fourth participant, CAP129, sampled prior to a detect-
able HIV antibody response, the Q182T mutation was already
present. The mutation remained stable for up to 28 weeks; how-
ever, by 32 weeks the Q182S mutation emerged. Since the Q182X
mutation in the TL9 epitope was detected in the earliest sample
sequenced from three of the 37 CAPRISA participants who were
FIG 2 Association between viral load (VL) and CD4 T-cell counts prognostic markers and HLA-B*81:01 and HLA-B*39:10 alleles at 12 and 36 months
postinfection. (A and C) Log10 VL values compared between individuals without and with HLA-B*81:01, HLA-B*39:10, or HLA-B*57:03/58:01 alleles at 12 and
36 months postinfection; (B and D) CD4 T-cell counts compared between individuals without and with HLA-B*81:01, HLA-B*39:10, or HLA-B*57/58:01
alleles at 12 and 36 months postinfection, respectively. B*81:01-positive participants shown as empty symbols are those positive for the Cw*04:01 allele. Both
B*39:10-positive participants are also positive for the Cw*12:03 allele. Viral load and CD4 T-cell counts were calculated as medians of measurements taken at
three time points closest to these intervals. To not enrich for slow progressors, we included the last attained median values for viral load and CD4 T-cell counts
before the initiation of ARV therapy for individuals who had received treatment prior to 12 months (n  7) or 36 months (n  12) postinfection.
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TABLE 2 HLA-B*81:01, HLA-B*39:10, and other B7 allelic restricted sequence variations in and proximal to the TL9 epitope and putative
compensatory mutationsa
PIDb wpic
TL9 mutations Other mutations
El77 T180 Q182 T186 L188 T190 H219 I223 A248 M250 I256
CAP129 2 – – T – – – – H T – –
B*81:01 23 – – T – – – – H T – –
32 – – S – – – – H T – –
37 – S – – – – H T – –
42 – – S – – – – H T – –
54 – – S – – – – H T – –
106 – – S – – – – H T – –
CAP222 56 – – – – – – – A – – –
B*81:01 70 – – – – – – – A – – –
83 – – S (6/9) – – – – A – – V
95 – – S (1/6) – – – – A – – V
108 – – S (3/11) – – – – A – – V (3/11)
108 D A S S (1/11) – – – A – – –
108 D – S S (7/11) – – – V (2/7) – – –
122 D – S S (13/13) – – – V 13/13 – – –
133 D – S S – – – V (13/13) – – –
148 D – S S – – – V – – –
161 D – S S – – – V – – –
174 D – S S – – – V (13/13) – – –
190 D – S S – – – V – – –
CAP225 50 – – – – – – – – – – –
B*81:01 61 – – S (10/15) – – – – – – – V (10/15)
74 – – S – – – – – – – V
85 – – S (3/15) – – – – – – – V (3/15)
98 – – S – – – – – – – V
117 – – S – – – – – – – V
130 – – S – – – – – – – V
145 – – S – – – – – – – V
158 – – S – – – – – – – V
171 – – S – – – – – – – V
183 – – S – – – – – – – V
CAP277 16 – – – – – – – – – I –
B*81:01 41 – – – – – – – – – I –
46 – – – – – – – – – I –
50 – – H – – – – – – I –
54 – – T – – – – – – I –
58 – – T – – – – – – I –
71 – – A – – – – – – I –
84 – – S – – – – – – I –
97 – – S (3/13) – – – – – – I (3/13) –
97 – – S S (6/13) – – – – – – (6/13) –
97 – – – – – – – – – – (4/13) –
110 – – S S – – – – T – –
123 – – S S – – – – T – –
137 – – S S – – – – T – –
CAP262 70 – – – – – – – – – – –
B*81:01 84 – – – – – – – – – – –
B*42:01 95 – – – – – – – – – – –
109 – – – – – – – – – – –
122 – – – – – – – – – – –
136 – – – – – – – – – – –
CAP278 9 D – S S – – – V – – –
B*39:10 54 D – S S – – – V – – –
85 D – S S – – Q V – – –
(Continued on following page)
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negative for HLA-B7 supertype alleles, it is possible that this mu-
tation was present in the transmitted virus. This is supported by
the fact that there was no evidence of an immune response to this
epitope in acute infection (Table 3). There was no sequence evo-
lution in the TL9 epitope in the fifth B*81:01 participant
(CAP262).
The viruses from the two B*39:10-positive participants had a
different pattern of escape. In one B*39:10 participant (CAP278),
all three mutations (E177D, Q182S, and T186S) were already pres-
ent in the earliest sequences available at 9 weeks postinfection,
with no further evolution within the epitope during 22 months of
follow-up. In the second B*39:10 participant (CAP289), the
Q182A mutation was present at 8 weeks postinfection and evolved
to Q182G at 28 weeks postinfection.
To evaluate the likelihood of the HLA-B*39:10-associated mu-
tations in residues E177, Q182, and T186 being present on the
transmitted virus in CAP278, we estimated the frequency of TL9
mutations in participants negative for HLA-B7 supertype and
Cw*08:02 alleles that recognize this epitope (35) in the CAPRISA
002 cohort. We found no sequences from either acute or chronic
infection with either the two (Q182S with T186S) or the three
(E177D, Q182S, and T186S) concurrent mutations. Furthermore,
the triple mutation was not present in any of the sequences ana-
lyzed from 507 HIV-1 subtype C-infected adults in Durban, Kwa-
Zulu-Natal, South Africa (30, 48).
Together, these results show that the TL9 escape in B*81:01
generally occurs later and can take approximately 1 year from the
first mutations for escape in this epitope to reach fixation. Fur-
thermore, we show that the three concurrent E177D, Q182S, and
T186S site mutations are rare and might have arisen due to early
escape in one of the two B*39:10-positive participants, although it
cannot be excluded that some of these mutations were transmitted
variants from a B7 supertype donor.
HLA-B*81:01 and HLA-B*39:10 exert more selection pres-
sure on TL9 than HLA-B*42 and HLA-B*07:02. Previous studies
have shown that the strength of immune responses targeting the
TL9 epitope differ according to the HLAs belonging to HLA-B7
supertype with HLA-B*81:01 being most dominant, followed by
HLA-B*39:10 and then HLA-B*42:01 (34). Since three partici-
pants in the present study were also positive for the HLA-B42
allele, we wanted to know the frequency of HLA-mediated se-
quence evolution in the TL9 epitope in participants carrying
HLA-B7 supertype (n  17), excluding the HLA-B*81:01/39:10-
positive participants. Analysis of sequences at 18 months postin-
fection revealed that only two of the 13 B*42:01-positive partici-
pants developed polymorphisms in the epitope (Table 2), whereas
no mutations were detected in the four B*07:02-positive partici-
pants (Table 3). In one of the two B*42:01-positive participants
who selected mutations in the TL9 epitope, an escape mutation
L188F emerged between 51 and 76 weeks; however, this mutation
was not fixed since it was not detected at 102 weeks postinfection
(Table 2). In the second participant, the Q182T mutation was
selected between 48 and 53 weeks postinfection, while four of the
five B*81:01-positive individuals selected for 182S. A recent study
analyzing 2,126 chronically HIV-1 subtype C-infected, antiretro-
viral naive adults showed that unlike the B*81:01 allele that select
against the Q182T mutation, the B*42:01 allele selected for Q182T
(6). Thus, the differences in escape at residue 182 provide further
support that B*81:01 restriction is responsible for the changes in
the TL9 epitopes. These results support the findings of Leslie et al.
(34), which demonstrated that B*81:01 and B*39:10 alleles select
for mutations in the TL9 epitope over the HLA-B*42:01 allele.
Overall, these findings emphasize the differential role of closely
related HLA in the timing of epitope escape and sequence evolu-
tion.
Late sequence evolution in TL9 is not due to the lack of CTL
responses in acute infection. A lack of CTL pressure in acute
infection has been suggested to partly explain why some epitopes
remain invariant through acute infection and only evolve late in
infection (24). IFN- ELISpot data are available for 13 partici-
pants with HLA-B7 supertype alleles (Table 3). Responses to the
TL9 epitope were identified in nine participants, with the magni-
tude of responses in B*81:01-positive participants being generally
higher, ranging from 100 up to 9,078 SFU/106 cells, compared to




TL9 mutations Other mutations
El77 T180 Q182 T186 L188 T190 H219 I223 A248 M250 I256
CAP289 8 – – A – – – – V – – V
B*39:10 24 – – A – – – – V – – V
28 – – G – – – – V – – V
41 – – G – – – – V – – V
CAP061 14 – – – – – – Q V – – –
B*42:01 33 – – – – – – Q V – – –
C*08:02 51 – – – – – – Q V – – –
76 – – – – F – Q V – I –
102 – – – – – – – V – – –
CAP282 11 – – – – – – – – – – V
B*42:01 35 – – – – – – – – – – V
53 – – T – – – – – – – V
a The commonly evolving amino acid residues are indicated in lowercase italics in the peptide 176-SeGATPqDLNtML-188. –, No residue substitution or else the incoming residue is
indicated; ND, not done or not available. Where applicable, the ratio of the number of mutations detected/total is indicated in parentheses.
b PID, participant identification number.
c wpi, weeks postinfection.
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TABLE 3 Temporal pattern of TL9-specific IFN- ELISpot assay responses inB7-positive participants
PIDa HLAb wpic SFU/106 cellsd Last WT and first TL9 mutatione













83 ND WT/Q182S (mixed)
108 1,233 Q182S/and E177D with T186S (mixed)
122 ND E177D, Q182S, T186S (fixed)













61 ND WT/Q182S (mixed)
85 Neg WT/Q182S (mixed)
145 1,221 Q182S (fixed)






CAP277 A*30:09, A*43:01; B*58:02, B*81:01; Cw*04:01, Cw*04:01 37 6,147
46 ND WT
50 ND Q182H
97 193 WT/Q182S/T186S (mixed)
CAP278 A*30:01, A*43:01; B*39:10, B*42:02; Cw*12:03, Cw*17:01 8 117 ND
9 ND E177D, Q182S, and T186S
10 Neg
CAP289 A*30:02, 68:01; B*39:10, B*58:02; Cw*06:02, Cw*12:03 8 ND Q182A
9 Neg
28 ND Q182G
CAP037 A*23:01, A*24:02; B*07:02, B*53:01; Cw*17:01, Cw*17:01 122 273 WT
CAP040 A*30:01, A*30:02; B*15:10, B*42:01; Cw*03:04, Cw*17:01 106 293 WT
CAP220 A*30:04, A*74:01; B*42:01, B*42:01; Cw*17:01, Cw*17:01 68 373 WT
CAP239 A*01:23, A*29:02; B*42:01, B*58:01; Cw*06:02, Cw*17:01 67 258 WT
CAP269 A*02:05, A*68:02; B*07:02, B*58:02; Cw*06, Cw*07 120 Neg WT
CAP282 A*30:01, A*66:01; B*42:01, B*58:02; Cw*:ND 23 129
35 ND WT
53 ND Q182T first observed at 12 months postinfection
60 Neg
a PID, participant identification number.
b HLAs known to restrict TL9 are underlined.
c wpi, weeks postinfection.
d ND, not done; Neg, negative; SFU, spot-forming units.
e WT, wild type. Mixed, a population in which more than one viral variant was identified; fixed, a population in which only one viral variant was identified.
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Of the five B*81:01-positive participants, four targeted the TL9
epitope with responses detected in acute infection for three par-
ticipants and at 9 months for one participant (CAP277) (earliest
sample tested). Three B*81:01-positive participants had strong
TL9 responses (1,569 to 9,078 SFU/106 cells) and, despite these
strong responses, escape only occurred 10 to 12 months after the
first detectable responses. We did not detect escape during the 33
months of follow-up in the fourth B*81:01-positive (CAP262)
participant with detectable but low TL9 responses (250 SFU/106
cells). The one B*81:01-positive participant (CAP129) who har-
bored an escape mutant at 2 weeks postinfection did not have
detectable responses to TL9 in the first 6 months of infection. Only
one of the B*39:10-positive participants had detectable responses
to TL9 during acute infection (CAP278). The peptide used to de-
tect responses corresponded to the wild-type sequence, and it is
possible that responses in individuals harboring TL9 escape vi-
ruses in very early infection could be missed due to differences in
the viral mutant and the peptide used.
Other than the B*81:01/39:10-positive participants, immune
responses at later time points (12 months postinfection) were
generated for six of the 19 participants positive for other HLA-B7
supertype and Cw*08:02 alleles known to target the TL9 epitope.
Low-magnitude responses (129 to 273 SFU/106 cells) were de-
tected in five of the six participants tested; however, only one of
these participants (CAP282) developed an escape mutant
(Q182T).
Similar to a previous study in this cohort (43), fluctuations in
immune response were not necessarily related to immune escape.
Due to the limited availability of specimens, it was not possible to
accurately determine the effect of sequence changes on immune
responses. However, loss of responses with concomitant sequence
change was detected in three individuals (CAP225, CAP278, and
CAP282).
Sequence evolution in the TL9 epitope is associated with co-
varying sites outside of the epitope. Studies have found signifi-
cant associations between mutations in the TL9 epitope and
highly variable residues (Gag residues 138, 228, 248, 252, and 256)
located in or flanking the three tropism-determining loops of p24
involved in the recognition of host factors necessary for virus rep-
lication or inhibition (loops 1 to 3 located at Gag residues 137 to
147, 214 to 225, and 248 to 254, respectively) (5, 10, 28, 47). We
investigated whether we could detect mutations in these tropism-
determining loops that were coselected with TL9-associated mu-
tations. We identified variation in five residues, at positions 219,
223, 248, 250, and 256, with the residues 219 and 223 located in the
second loop, which contains the cyclophilin A binding sites, and
residues 248, 250, and 256 located in or proximal to the third loop
(Table 2).
We investigated coselection using approaches that couple phy-
logenetic and Bayesian network models in Spidermonkey (45)
using 463 CAPRISA longitudinal population sequences, including
more than 120 clones from four B*81:01-positive participants at
selected time points (Table 2) and found significant correlation
between various sites: 186S with 177D, 182S with 256V, and 186S
with 250M (posterior probability  0.5) (Table 4). In the longi-
tudinal analysis in CAP277, the emergence of T186S mutation was
accompanied with evolution of sites, 248 and 250 (Table 2). Inter-
estingly, every sequence carrying the TL9 double mutations
(Q182S and T186S) was associated with reversion of the M250I
mutation, suggesting a selective reversion to accommodate the
double TL9 mutations. Similarly, the fixation of the triple muta-
tions E177D, Q182S, and T186S at around 122 weeks in CAP222
was preceded by significant toggling in the epitope, as well as a
reversion in a putative compensatory site V223A (Table 2) (P 
0.0035), suggesting that the evolution of mutation V223A was
under selective reversion (12). Furthermore, in CAP222, as well as
in CAP225, the evolution of the single Q182S mutation in the TL9
epitope was accompanied by the emergence of a Gag I256V mu-
tation (Table 2). In three other participants (CAP129, CAP278,
and CAP289) combinations of mutations (Q182T/A248T,
E177D/Q182S/T186S/I223V, and Q182A/I223V/I256V, respec-
tively) were present in the first sample analyzed. Sequence evolu-
tion at site 190 has been shown to compensate for escape in TL9
epitope through the T186S mutation (56, 57). However, we found
no sequence evolution at this residue (T190) in any of the B7-
positive individuals or in any of the other participants investigated
here (Table 2).
The timing of the sequence evolution influenced the differ-
ential disease progression among the B*81:01- and B*39:10-
positive participants. In vitro studies have demonstrated that
substitution in the TL9 epitope residue T186 alone (56, 57) or in
both T186 and E177 (47) incurs a fitness cost to the virus, whereas
mutations at residue Q182 revert to consensus after transmission
to HLA-mismatched recipients (39). Moreover, a recent study
demonstrated that in a subtype C Gag backbone Q182S incurs a
fitness cost to the virus in vitro (57).
In order to understand CTL-mediated escape and its impact on
disease progression, we investigated the temporal relationship be-
tween sequence evolution in the TL9 epitope and viral loads and
CD4 T-cell counts in B*81:01- and B*39:10-positive participants
(Fig. 3A). No escape was detected in virus from CAP262, who
elicited immune responses to TL9 in early infection and gradually
controlled viral load to levels below 2,000 copies/ml after 24
months postinfection. We found that evolution of a single site,
Q182 in the TL9 epitope in tandem with putative compensatory
mutations A248T or I256V, did not affect viral loads or CD4
T-cell counts in the three typical progressors—CAP129, CAP225,
and CAP289 —for at least the first 24 months after escape. These
participants maintained consistently high viral loads for at least
the first 3 years postinfection. Interestingly, characteristic of es-
cape from a dominant response (9, 14, 23), the spontaneous in-
crease in viral load and reduction in CD4 T-cell counts in two
individuals controlling viremia, CAP222 and CAP277, coincided
with late sequence evolution in three (E177D, Q182S, and T186S)
and two (Q182S with T186S) sites, respectively, together with re-
version of putative compensatory residues I/V223A and M250I,
respectively. Moreover, when the cost of escape in these two par-
ticipants was estimated by comparing the median viral load mea-
TABLE 4 Sites covarying with each other in three of the four individuals





CAP222 186S 177D 0.73
CAP222 182S 256V 0.73
CAP225 182S 256V 0.73
CAP277 186S 250M 0.79
a PID, participant identification number.
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surements for 9 months before escape and 9 months later, we
found that multiple residue escape was associated with a 1-log10
increase in viral load (Fig. 3B). This higher viral load was sustained
for approximately 9 months after escape, after which it subsided,
although to a level higher than before the escape (Fig. 3B). When
viral loads in these participants at 4 years postinfection were com-
pared to those who evolved single site escape mutation and to the
median value for the rest of the cohort (i.e., individuals with non-
FIG 3 (A) Viral load trajectories in the first 156 weeks (36 months) postinfection in B*81:01-positive (CAP129, CAP225, CAP222, CAP262, and CAP277) and
B*39:10-positive (CAP278 and CAP289) participants, illustrating the timing of TL9-associated escape. The broken black line illustrates the limit of detection of
the assay (400 copies/ml or 2.6 log10). Putative compensatory mutations are shown in italics. (B) Cost of multiple sequence evolution in or flanking the TL9
epitope in individuals who were controlling the infection, as measured by the change in viral load and longer follow-up showing the reduction in the maximum
viral load but to levels higher than before escape. Four values of log10 viral loads over 9 months were used to calculate the median viral load before multiple residue
escapes, after, and 40 weeks later. Putative compensatory mutations are shown in italics.
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protective alleles, including B*81:01/57/58:01/39:10-negative par-
ticipants) (Fig. 1), we found that both CAP277 and CAP222 still
had lower viral loads. Interestingly, the B*39:10-positive partici-
pant (CAP278), who had the same mutations in acute infection,
maintained low viral loads below 2,000 copies/ml over the 3-year
period.
DISCUSSION
The B-7 HLA restriction alleles, including HLA-B*07:02, HLA-
B*39:10, HLA-B*42:01, HLA-B*42:02, and HLA-B*81:01, are
common in Black Africans and were found at a frequency of 40%
(25/62) in the CAPRISA cohort. The TL9 epitope, located in p24
Gag, is an immunodominant epitope restricted by this HLA su-
pertype. These HLAs are less common in Caucasians and the dif-
ferential CTL targeting of Gag in Caucasians compared to Black
South Africans is largely due to differences in frequency of TL9
recognition (22). The significance of evaluating this epitope is
further emphasized by accumulating evidence showing that HLA-
B*39:10 and HLA-B*81:01 alleles are associated with better infec-
tion outcomes in subtype C infection in southern Africa (30, 33).
Aside from well-characterized epitopes associated with viral con-
trol, such as the B*57/58:01-restricted TW10, there is little known
about the influence of epitope escape on HIV infection of Afri-
cans. We report here on a longitudinal study of subtype C-infected
women from Kwazulu-Natal, South Africa, with acute to chronic
infections. This study allowed us to determine the timing of escape
in TL9 and identify coevolving sites, and it provided insights into
the impact of these mutations on disease progression.
Previous studies have shown that individuals carrying any of
the closely related HLA-B7 supertype alleles can mount a CD8
T-cell response that targets the TL9 epitope (25, 34), with the most
dominant being HLA-B*81:01, followed by HLA-B*39:10 and
then HLA-B*42:01 (34). Although B42 alleles may have contrib-
uted to the selection of mutations in TL9 in each of the two par-
ticipants positive for B*81:01 in combination with B42 allele (Ta-
ble 1), there were far fewer polymorphisms in viruses in
individuals positive for only B*42:01/42:02 alleles. Our results
confirm previous observations that B*81:01 exert the greatest se-
lective pressure on the virus (34) (Table 5), at least for the first 18
months postinfection. Different patterns of escape and generally
higher TL9 specific immune responses seen in B*81:01-positive
individuals compared to other B7-positive individuals confirm
previously reported differences in recognition and selection pres-
sure by the different HLAs belonging to the HLA-B7 supertype
(18, 34).
We documented the emergence of known B*81:01 escape mu-
tations (E177D, Q182S, and T186S) (34) and identified a common
pattern of evolution with the Q182S mutation generally emerging
prior to T186S. Unlike the B*57/58:01-restricted TW10 escape,
which usually occurs rapidly and during acute and early infection
(7, 9, 37), escape in women with a B*81:01 background was usu-
ally late and took nearly a year to reach fixation. In late infection,
slow escape has been postulated to be due to a number of factors,
including low selection pressure, an increased diversity of specific
responses, and raised viral fitness cost (17, 36, 49). Indeed, in vitro
studies have demonstrated that T186S mutation alone (56) or in
combination with E177D (56, 57) incurs a fitness cost to the virus.
Interestingly, we found that late evolution of T186S either alone or
in combination with E177D coincided with an increase in viral
load and although viral replication was subsequently brought un-
der control, it returned to a level higher than before escape. This
reflects the complex balance between the host and the virus, where
immune escape results in loss of control and is thus detrimental to
the host; however, the impact of the mutation on viral replication
capacity provides some benefit. Of interest, Wright et al. (56, 57)
demonstrated that individuals carrying both 182S and/or 190X
and 186S had higher replication capacities than individuals with
186S alone, although in our study we did not observe a single 186S
and/or 190X mutation.
Although escape mutations that reduce viral fitness often select
for variants that affect structural and/or reduced function (10, 46,
49, 50), the development of mutations that compensate for the
fitness cost in the TL9 epitope are not well described. However,
although in vitro studies for the Q182S mutation alone yielded
discordant replication results, experiments in a subtype C Gag
backbone found that Q182S incurred a fitness cost to the virus and
same level of replication for either T186S alone or both T186S and
Q182S (57). A recent cross-sectional study on sequences from 662
individuals infected with HIV-1, subtype C, found that polymor-
phism at I256 was significantly associated with the B*81:01-re-
stricted Q182 and T186 sites (10). Here, we found concomitant
evolution of I256V in each sequence carrying the Q182X muta-
tion, providing further support that this mutation compensates
for the fitness cost due to sequence evolution at site 182. However,
the replication cost for this site mutation with the coevolving site
remains to be determined in vitro.
In vitro studies have demonstrated that mutations in residues
H219, I223, and M228 compensate for the fitness cost due to the
T242N escape mutation in B*57/58:01 restricted TW10, whereas
A248T and M250I have been associated with TW10 escape (4, 10,
37). We found an overlap in sites associated with B*81:01/39:10-
restricted TL9. The development of both Q182S and T186S mu-
tations in TL9 was associated with reversion to M250. Similarly,
we found that fixation of the three escape residues at 2 years
postinfection in CAP222 was associated with selective reversion of
the transmitted mutation I/V223A in the cyclophilin binding
loop, whereas the H219Q mutation in Gag subsequently devel-
oped 17 months postinfection in one of the controllers (CAP278).
These common evolutionary pathways associated with TW10/
TL9 restriction may be due to functional and structural interac-
tions between the region harboring these epitopes (37, 51). These
results support the model proposed by Crawford et al. (10), in
which exposed capsid variable-residues generically compensate
for fitness cost due to selection in structurally and functionally
conserved capsid residues. The findings described here also sup-
TABLE 5 Differences in the rate of escape in participants positive for
the HLA- B7 supertype and Cw*08:02 alleles that target TL9 epitope
Timea
(mo postinfection)











Enrollment 1 and 1* 0 0 1* 0
3 0 0 0 0 0
3–6 0 0 0 0 0
6–12 1* 1† 0 1 and 1* 0
12–18 0 1‡ 0 2 0
a The time corresponds to when the first mutation was observed in TL9 epitope in the
CAPRISA (AI02) cohort.
b *, Participants with mutation at enrollment but with later further evolution of the
mutation; †, mutation Q182T; ‡, mutation L188F was transient.
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port common compensatory pathways of viral evolution in vari-
able domains associated with host tropism.
In conclusion, these findings expand our understanding of
why some individuals with so-called beneficial alleles do not con-
trol viral replication. We provide here in vivo evidence that late
escape at multiple sites both in and proximal to the TL9 epitope is
associated with increased viremia in subtype C HIV-1-infected
individuals, and we expand our knowledge regarding characteris-
tics of Gag epitopes that are important to take into account when
designing vaccine strategies.
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